StreetInsider.com News Articles

Form SC TO-I Arbutus Biopharma Corp Filed by: Arbutus Biopharma Corp

Mon, 24 Aug 2026 08:24:00 -0400

si-local-file:///var/storage/secattach/20260824/26964565.html

Form SC TO-I Arbutus Biopharma Corp Filed by: Arbutus Biopharma Corp

Mon, 24 Aug 2026 08:24:00 -0400

si-local-file:///var/storage/secattach/20260824/26964565.html

Arbutus Biopharma launches $230M Dutch auction tender offer

Mon, 24 Aug 2026 07:30:47 -0400

Arbutus Biopharma Corporation (Nasdaq: ABUS) has commenced a modified "Dutch Auction" tender offer to repurchase up to $230 million of its common shares at a price between $5.00 and $5.75 per share, according to a company statement.

The offer began Aug. 24, 2026, and is set to expire at 5:00 p.m. New York City time on Sept. 29, 2026, unless extended or terminated. As of Aug. 19, 2026, there were 198,105,743 shares issued and outstanding. If fully subscribed, the repurchase would represent between 20.2% and 23.2% of outstanding shares, depending on the final purchase price.

The closing price of Arbutus shares on

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Mon, 24 Aug 2026 07:30:00 -0400

WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the commencement of a modified “Dutch Auction” tender offer to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”) at a price of not less than US$5.00 and not more than US $5.75 per Share, less any applicable withholding taxes and without interest, on the terms and subject to the conditions described in the offer to purchase and accompanying issuer bid circular, dated August

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Mon, 24 Aug 2026 07:30:00 -0400

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Mon, 24 Aug 2026 07:30:00 -0400

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Mon, 24 Aug 2026 07:30:00 -0400

Form SC TO-C Arbutus Biopharma Corp Filed by: Arbutus Biopharma Corp

Fri, 21 Aug 2026 08:04:00 -0400

si-local-file:///var/storage/secattach/20260821/26958623.html

Form SC TO-C Arbutus Biopharma Corp Filed by: Arbutus Biopharma Corp

Fri, 21 Aug 2026 08:04:00 -0400

si-local-file:///var/storage/secattach/20260821/26958623.html

Form 8-K Arbutus Biopharma Corp For: Aug 21

Fri, 21 Aug 2026 07:53:00 -0400

si-local-file:///var/storage/secattach/20260821/26958534.html

Form 8-K Arbutus Biopharma Corp For: Aug 21

Fri, 21 Aug 2026 07:53:00 -0400

si-local-file:///var/storage/secattach/20260821/26958534.html

Arbutus plans $230M share repurchase via Dutch auction tender offer

Fri, 21 Aug 2026 07:30:35 -0400

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced plans to launch a modified "Dutch Auction" tender offer to repurchase up to $230 million of its common shares, according to a press release.

The company said the offer price range would be between $5.00 and $5.75 per share in cash, less any applicable withholding taxes and without interest. The offer is expected to commence on or about Aug. 24, 2026, and expire on or about Sept. 29, 2026, unless extended or terminated. Arbutus said the offer would be funded through cash on hand.

The offer is subject to receiving exemptive relief under applicable securities laws

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Fri, 21 Aug 2026 07:30:00 -0400

WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified “Dutch Auction” tender offer (the “Offer”) to repurchase up to US$230 million of its common shares at a purchase price of not less than US$5.00 per share and not more than US$5.75 per share, in cash, less any applicable withholding taxes and without interest. The Offer is expected to commence on or about August 24, 2026 and, unless extended or terminated by the Company, expire

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Fri, 21 Aug 2026 07:30:00 -0400

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Fri, 21 Aug 2026 07:30:00 -0400

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Fri, 21 Aug 2026 07:30:00 -0400

Form SCHEDULE 13G/A Arbutus Biopharma Corp Filed by: MORGAN STANLEY

Wed, 12 Aug 2026 15:02:00 -0400

si-local-file:///var/storage/secattach/20260812/26912194.html

Form SCHEDULE 13G/A Arbutus Biopharma Corp Filed by: MORGAN STANLEY

Wed, 12 Aug 2026 15:02:00 -0400

si-local-file:///var/storage/secattach/20260812/26912194.html

Arbutus Biopharma (ABUS) Reports In-Line Q2 EPS

Wed, 12 Aug 2026 07:50:04 -0400

Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $10 thousand versus the consensus estimate of $450 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

Form 10-Q Arbutus Biopharma Corp For: Jun 30

Wed, 12 Aug 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260812/26908956.html

Form 10-Q Arbutus Biopharma Corp For: Jun 30

Wed, 12 Aug 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260812/26908956.html

Form 8-K Arbutus Biopharma Corp For: Aug 12

Wed, 12 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26908950.html

Form 8-K Arbutus Biopharma Corp For: Aug 12

Wed, 12 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26908950.html

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 07:30:00 -0400

Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026

Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus shareholders

Filed three international patent enforcement lawsuits against Pfizer and BioNTech related to lipid nanoparticle (LNP) technology

Achieved alignment with the U.S. Food and Drug Administration (FDA) on a proposed imdusiran Phase 2b clinical trial design

WARMINSTER, Pa., Aug. 12, 2026

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 07:30:00 -0400

Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026

Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus shareholders

Filed three international patent enforcement lawsuits against Pfizer and BioNTech related to lipid nanoparticle (LNP) technology

Achieved alignment with the U.S. Food and Drug Administration (FDA) on a proposed imdusiran Phase 2b clinical trial design

WARMINSTER, Pa., Aug. 12, 2026